



Mamta Parikh, M.D., M.S.

Philosophy of Care

Dr. Parikh believes that every cancer patient deserves a compassionate and clear explanation of their diagnosis as well as their treatment options. She believes in the importance of clinical research, which has resulted in new, more effective therapies for the treatment of genitourinary malignancies, and offers hope for the future of how these cancers are treated. She strives to provide the best possible care for patients, providing the latest advances in therapy, offering participation in clinical trials which have the potential to further scientific advances and improving outcomes, and involving other specialists so that patients receive the best multidisciplinary treatment.

Clinical Interests

Dr. Parikh is a medical oncologist specializing in the treatment of genitourinary malignancies, including bladder cancer, kidney cancer, prostate cancer, and testicular cancer.

Research/Academic Interests

Dr. Parikh's research focuses on improving outcomes in bladder, kidney, and prostate cancer, by investigating new agents in clinical trials in patients with these malignancies, and also by looking at cancer outcomes in California. She has particular clinical research interests in improving the effect of immunotherapy in bladder cancer.

Title Assistant Professor, Division of Hematology and Oncology

Specialty Genitorurinary

Department [Internal Medicine](#)

Division Hematology and Oncology

Clinic Hematology/Oncology Clinic

Center/Program Affiliation [UC Davis Comprehensive Cancer Center](#)

Address/Phone UC Davis Comprehensive Cancer Center, Hematology/Oncology Clinic, 4501 X Street 2nd Floor
Sacramento, CA 95817

Phone: 916-734-5959

Additional Phone Phone: 916-734-3772
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Education M.D., UC Davis School of Medicine, Davis CA 2011
M.S., Organic Chemistry, UC Irvine, Irvine CA 1997
B.S., Chemistry, Boston University, Boston MA 1995

Internships Internal Medicine, UC Davis Medical Center, Sacramento CA 2011-2012



Mamta Parikh, M.D., M.S.

Residency	Internal Medicine, UC Davis Medical Center, Sacramento CA 2012-2014
Fellowships	Hematology/Oncology, UC Davis Medical Center, Sacramento CA 2014-2017
Board Certifications	American Board of Internal Medicine American Board of Internal Medicine, Hematology and Oncology American Board of Internal Medicine, Medical Oncology
Professional Memberships	American Association for Cancer Research American Society of Clinical Oncology Association of Northern California Oncologists Southwest Oncology Group (SWOG)
Honors and Awards	K12 Paul Calabresi Career Development for Clinical Oncology, National Cancer Institute, 2018 Joseph Sullivan Research Award, UC Davis Comprehensive Cancer Center, 2016 Allan T. Nunn Memorial Scholarship, UC Davis School of Medicine, 2011 American Institute of Chemists Award, American Chemical Society, 1995
Select Recent Publications	Wang G, Nardo L, Parikh M, Abdelhafez YG, Li E, Spencer BA, Qi J, Jones T, Cherry SR, Badawi RD. Total-Body PET Multiparametric Imaging of Cancer Using a Voxel-wise Strategy of Compartmental Modeling. J Nucl Med. 2021 Nov 18;jnumed.121.262668. doi:10.2967/jnumed.121.262668. Epub ahead of print. PMID:34795014. Parikh M. Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time? J Kidney Cancer VHL. 2021 Oct 14;8(4):20-21. doi:10.15586/jkcvhl.v8i4.207. PMID:34722127. Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN Jr. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1536-1543. doi:10.1001/jamaoncol.2021.3441. PMID:34436521. Parikh M, Powles T. Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. Am Soc Clin Oncol Educ Book. 2021 Jun;41:e182-e189. doi:10.1200/EDBK_323835. PMID:34061558.



Mamta Parikh, M.D., M.S.

Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. *Sci Rep*. 2021 Mar 18;11(1):6377. doi:10.1038/s41598-021-85969-x. PMID:33737681.

Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. *Semin Nephrol*. 2020 Jan;40(1):76-85. doi:10.1016/j.semnephrol.2019.12.009. PMID:32130969.

Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN Jr. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. *Clin Genitourin Cancer*. 2018 Dec;16(6):421-428.e1. doi:10.1016/j.clgc.2018.07.004. Epub 2018 Jul 12. PMID:30166228.

Parikh M, Galkin M, Brunson A, Keegan T, Chew HK. Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer. *Cancer Treat Res Commun*. 2018; 16:38-44. doi:10.1016/j.ctarc.2018.06.001. Epub 2018 Jun 13. PMID:31299001.

Parikh M, Lara PN Jr. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. *Annu Rev Med*. 2018 Jan 29;69:209-221. doi:10.1146/annurev-med-041916-124132. Epub 2017 Nov 16. PMID:29144835.

Lara PN Jr, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. *JCO Precis Oncol*. 2017;2017:PO.17.00065. doi:10.1200/PO.17.00065. Epub 2017 Nov 2. PMID: 29629426.



Mamta Parikh, M.D., M.S.

© 2024 UC Regents